Elicio Therapeutics, Inc.

Stocks

ELTX

US28657F1030

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2026-07-20			5-day change	1st Jan Change
3.040 ^USD	-2.25%		-7.60%	-61.81%

Jul. 06	Elicio Therapeutics Closes $15 Million Registered Direct Offering	MT
Jul. 02	Top Midday Decliners	MT

Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

Published on 03/12/2026 at 04:25 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

ELICIO THERAPEUTICS, INC.

-2.25%

Elicio Therapeutics, Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported net loss was USD 39.57 million compared to USD 51.9 million a year ago. Basic loss per share from continuing operations was USD 2.58 compared to USD 4.25 a year ago.

Add MarketScreener to your sources

Latest news about Elicio Therapeutics, Inc.

Jul. 06	Elicio Therapeutics Closes $15 Million Registered Direct Offering	MT
Jul. 02	Top Midday Decliners	MT
Jul. 02	Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June	MT
Jul. 02	Top Premarket Decliners	MT
Jul. 02	Elicio Therapeutics Prices $15 Million Direct Offering	MT
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 2000 Index	CI
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 2500 Growth Benchmark	CI
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell Microcap Value Benchmark Index	CI
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell Microcap Growth Benchmark Index	CI
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 2000 Growth Benchmark	CI
Jun. 29	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 3000E Growth Benchmark	CI
Jun. 28	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Value Benchmark	CI
Jun. 28	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 3000 Growth Benchmark	CI
Jun. 28	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell 2000 Dynamic Index	CI
Jun. 28	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell Small Cap Completeness Index	CI

Chart Elicio Therapeutics, Inc.

Duration

Period

ELTX: Dynamic Chart

Company Profile

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Companyâ€™s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company